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Background: The oral proteasome inhibitor ixazomib is under phase 3 clinical investigation in multiple myeloma
(MM) in combination with lenalidomide–dexamethasone. This study was conducted to investigate the
pharmacokinetic and safety profiles of ixazomib, administered with lenalidomide–dexamethasone, in East Asian
patients with relapsed/refractory MM.
Methods: Adult patients with measurable disease who had received 1–3 prior lines of therapy received oral
ixazomib on days 1, 8, and 15, lenalidomide (25 mg) on days 1–21, and dexamethasone (40 mg) on days 1, 8, 15,
and 22, in 28-day cycles. Primary objectives were to characterize ixazomib plasma pharmacokinetics, determine the
recommended phase 2/3 dose, and evaluate safety and tolerability.
Results: Forty-three patients were enrolled. No dose-limiting toxicities were reported for the first six patients
receiving ixazomib (4.0 mg), confirming this as the recommended phase 2/3 dose. Ixazomib was rapidly absorbed
with a median Tmax of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life
of 6.1 days. Twenty-one (49 %) patients had at least one drug-related grade ≥3 adverse event (AE); the most
common were neutropenia (19 %), diarrhea (14 %), and thrombocytopenia (12 %). Twenty-eight of 43 (65 %)
response-evaluable patients had at least a partial response. The recommended phase 2/3 dose for ixazomib was
determined to be 4.0 mg.
Conclusions: The all-oral combination of ixazomib plus lenalidomide–dexamethasone appeared active and well
tolerated at 4.0 mg. Consequently, East Asian patients enrolled in phase 3 studies are receiving the same ixazomib
dose as patients in other regions.
Trial registration: This study is registered at NCT01645930.
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Multiple myeloma (MM) is one of the most common
hematologic malignancies, with approximately 86,000
new cases and 63,000 deaths reported globally each
year [1], with recent reports suggesting that the inci-
dence is increasing in some Asian countries [2]. The
benefits of combining a proteasome inhibitor with an
immunomodulatory drug and dexamethasone have
been demonstrated in several clinical trials in patients
with newly diagnosed MM (NDMM) [3–7] and in pa-
tients with relapsed and/or refractory MM (RRMM)
[8–10], including Asian patients [11]. Substantial activ-
ity, including rapid and deep responses and prolonged
progression-free survival, has been reported with bortezo-
mib in combination with lenalidomide and dexametha-
sone and, more recently, carfilzomib plus lenalidomide
and dexamethasone [5–7, 9, 10]. Following recent im-
provements in response rates and survival with the
use of proteasome inhibitors and immunomodulatory
drugs, and in the context of a growing interest in
both maintenance and continuous therapy, there is an
increased focus on long-term treatment and patient
quality of life [12]. However, the feasibility of long-
term treatment with current proteasome inhibitors
may be limited for many patients due to toxicities or
the need for regular clinic visits for intravenous/sub-
cutaneous drug administration.
The investigational proteasome inhibitor ixazomib
is the first orally administered proteasome inhibitor
to be investigated in the clinic [13–16]. Phase 1
studies showed single-agent ixazomib to be generally
well tolerated, with encouraging evidence of prelim-
inary activity in patients with RRMM [13, 15]. The
feasibility of combining ixazomib with lenalidomide
and dexamethasone has been demonstrated in a
phase 1/2 study in patients with NDMM; the results
indicated a very high response rate (90 % overall re-
sponse rate [ORR]) at the recommended phase 2/3
dose (RP2/3D) of ixazomib (4.0 mg), including 62 %
very good partial response (VGPR) or better, with a
manageable toxicity profile, including limited periph-
eral neuropathy (PN) [14]. On the basis of these
early-phase data, phase 3 clinical trials are currently
ongoing to assess the all-oral combination of weekly
ixazomib (4.0 mg) plus lenalidomide and dexamethasone
in patients with RRMM (NCT01564537) and NDMM
(NCT01850524).
As the pharmacokinetic (PK) and safety profiles of
a drug can be affected by ethnicity [17–19], this
phase 1 PK study (NCT01645930) was conducted to
investigate the PK and safety profiles of weekly oral
ixazomib in combination with lenalidomide and dexa-
methasone and to determine the ixazomib RP2/3D
specifically in East Asian patients with RRMM.Results
Patients and treatment exposure
A total of 43 East Asian patients were enrolled. Patient
baseline demographics and disease characteristics are
shown in Table 1.
At the data cutoff (July 14, 2014), with enrollment
completed and all patients having received at least 1
treatment cycle (i.e., completed the PK cycle of the
study), the patients had received a median of 7 treat-
ment cycles (range, 1–20 cycles), with 27 (63 %) and 6
(14 %) patients having received ≥6 and ≥12 cycles, re-
spectively. A total of 22 patients (51 %) remained on
treatment, having received a range of 1 to 20 treatment
cycles. The mean relative dose intensity (proportion of
dose prescribed that was actually taken) was 89.6 % for
ixazomib, 68.7 % for lenalidomide, and 90.9 % for dexa-
methasone, with 12 (29 %), 5 (12 %), and 12 (28 %) of
patients receiving 100 % of the planned dose of each drug,
respectively; one patient received a lenalidomide starting
dose of 15 mg, and four received a lenalidomide starting
dose of 10 mg (all had creatinine clearance >50 mL/min).
DLTs and determination of the recommended phase 2/3
dose
No dose-limiting toxicities (DLTs) were reported for the
first six patients (three Chinese, three Indians) receiving
the starting dose of 4.0 mg ixazomib. The RP2/3D of
weekly ixazomib in combination with lenalidomide and
dexamethasone was therefore determined as 4.0 mg, and
all subsequently enrolled patients received 4.0 mg of
ixazomib.
As the study continued, 2 of 24 DLT-evaluable patients
experienced DLTs in cycle 1. One patient had drug-
related grade 3 elevated alanine aminotransferase, grade
2 elevated alkaline phosphatase, and grade 2 elevated γ-
glutamyltransferase, which, in the opinion of the investi-
gator, were related to the study drugs (drug relationship
was not reported for the three drugs separately); the
DLTs were resolved following a treatment delay and the
patient continued on study but received a reduced dose
of lenalidomide (15 mg). A second patient, with a history
of ongoing chronic atrophic gastritis and severe entero-
gastric reflux gastritis, had drug-related grade 3 diarrhea,
which, in the opinion of the investigator, was related to
lenalidomide; this DLT was resolved following patient
withdrawal from the study.
PK profile of ixazomib in combination with lenalidomide–
dexamethasone
Ixazomib was rapidly absorbed with a median time to
maximum plasma concentration (Tmax) of 1.5 h (range
0.5–8 h) on day 1 and 2.0 h (range 0.5–8 h) on day 15 of
cycle 1 (Table 2). The overall geometric mean (% coeffi-
cient of variation [CV]) Cmax (maximum observed plasma
Table 1 Patient baseline demographics and disease characteristics
Characteristic N = 43
Median age, years (range) 63 (38–79)
Male, n (%) 27 (63)













MM subtype, n (%)
IgG 27 (63)
IgA 5 (12)
Kappa light chain 5 (12)
Lambda light chain 2 (5)
Biclonal 1 (2)
Unknown 3 (7)




Median time since initial diagnosis to first dose
of ixazomib, months (range)
36.3 (8–116)











Prior transplant, n (%) 21 (49)
ECOG Eastern Cooperative Oncology Group, ISS International Staging System,
MM multiple myeloma
aOne patient had received five prior therapies
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centration–time curve from 0 to 168 h post-dose) values
on day 1 were 33.8 (115) ng/mL and 776 (78) hr*ng/mL,
respectively. The corresponding values on day 15 were
43.9 (72) ng/mL and 1610 (48) hr*ng/mL, respectively.
After multiple dosing, the terminal half-life was 6.1 days
and the accumulation ratio (day 15 AUC0–168/day 1 AUC0–
168) was 2.4 (Table 2). Mean plasma concentration–time
profiles on days 1 and 15 are shown in Fig. 1; the PK profiles
appeared similar across the different East Asian subgroups.
The dose-normalized (DN) AUC data for East Asian patients
from this study compared with Western patients (pooled
data from three phase 1/2 trials of patients with RRMM
(NCT00963820) [13], NDMM (NCT01217957) [14], and re-
lapsed/refractory amyloid light-chain (AL) amyloidosis
(NCT01318902) [16]) are shown in Fig. 2.Safety
All 43 patients received at least one dose of ixazomib
plus lenalidomide–dexamethasone and were included in
the safety population. All patients had at least one
treatment-emergent adverse event (TEAE), and 31
(72 %) had at least one grade ≥3 TEAE (Table 3). Drug-
related TEAEs and drug-related grade ≥3 TEAEs were
seen in 37 (86 %) and 21 (49 %) patients, respectively.
The most common any grade and drug-related grade ≥3
TEAEs are shown in Table 4; the most common grade ≥3
drug-related AEs included neutropenia (n = 8, 19 %),
thrombocytopenia (n = 5, 12 %), and diarrhea (n = 6,
14 %). Five (12 %) patients had a grade 4 drug-related
TEAE; the most common of which was thrombocytopenia
(four patients, 9 %), followed by hypokalemia, neutropenia,
and renal impairment (one patient each, 2 %). The case of
renal impairment improved following treatment; however,
the patient subsequently developed pneumonia and died
off-study, 42 days after receiving the last dose of study
drug.
Drug-related TEAEs in the skin and subcutaneous tis-
sue disorders, MedDRA System Organ Class, were re-
ported in 21 (49 %) patients (Table 4), including drug
hypersensitivity (grade 3 maculopapular rash) in one pa-
tient; this event was considered a serious drug-related
TEAE and led to discontinuation of lenalidomide. All
other rash-related events were grade ≤2 in intensity, and
none was serious. Drug-related PN not elsewhere classi-
fied was reported in 11 (26 %) patients. This was grade 1
in eight patients (19 %) and grade 2 in three patients
(7 %); there were no reports of grade ≥3 PN. Most (11/16,
67 %) cases of PN and peripheral sensory neuropathy were
unresolved at the time of data cutoff. None of the neur-
opathy events was serious. There were two cardiac AEs:
one patient had grade 1 angina pectoris, and one had
grade 1 palpitations, neither was considered related to
Table 2 Plasma PK parameters of ixazomib on day 1 and day 15 of cycle 1
Parameter Chinese Korean Othera Overall
Day 1 n = 16 n = 16b n = 6 n = 38c
Tmax, h
d 1.04 (0.5–7.0) 1.95 (0.5–8.0) 1.75 (0.5–7.0) 1.5 (0.5–8.0)
Cmax, ng/mL 50.6 (102) 22.1 (99) 35.7 (118) 33.8 (115)
AUC0–168, h*ng/mL 933 (83) 630 (47) 720 (63) 776 (78)
DN Cmax, ng/mL/mg 12.6 (102) 5.53 (99) 8.93 (118) 8.45 (115)
DN AUC0–168, h*ng/mL/mg 233 (83) 157 (47) 180 (63) 194 (78)
Day 15 n = 15e n = 13f n = 4 n = 32g
Tmax, h
d 2 (0.5–7.08) 2 (0.48–7.97) 1.25 (0.5–4.0) 2.0 (0.48–7.97)
Cmax, ng/mL 50.3 (71) 38.0 (67) 42.4 (97) 43.9 (72)
AUC0–168, h*ng/mL 1750 (39) 1450 (49) 1530 (81) 1610 (48)
DN Cmax, ng/mL/mg 12.6 (71) 9.51 (67) 10.6 (97) 11.0 (72)
DN AUC0–168, h*ng/mL/mg 438 (39) 362 (49) 383 (81) 401 (48)
t1/2, h 148 (20) 145 (20) 148 (7) 147 (18)
Accumulation ratio 2.38 (30) 2.34 (40) 2.56 (33) 2.39 (33)
Data are given as geometric mean (% CV), unless otherwise specified
AUC0–168 area under the plasma concentration–time curve from 0 to 168 h post-dose, Cmax maximum observed plasma concentration, DN dose-normalized, t1/2
half-life of the terminal disposition phase, Tmax time of Cmax
aDay 1: Malaysian (n = 3), Asian Indian (n = 2), Indonesian (n = 1); day 15: Malaysian (n = 3), Indonesian (n = 1)
bn = 12 for AUC0–168
cn = 34 for AUC0–168
dMedian (range)
en = 14 for t1/2 and n = 12 for accumulation ratio
fn = 11 for AUC0–168 and t1/2 and n = 9 for accumulation ratio
gn = 30 for AUC0–168, n = 29 for t1/2, and n = 25 for accumulation ratio
a b
Fig. 1 Mean plasma concentration–time profiles of ixazomib in combination with lenalidomide–dexamethasone on a day 1 and b day 15 of
cycle 1 (safety population)
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Fig. 2 Ixazomib dose-normalized AUC0–168 on day 1 (a) and day 15
(b) of cycle 1 in East Asian and Western patients. Box plots represent
the 25th, 50th, and 75th percentiles; whiskers denote the 10th and
90th percentiles. East Asian patients received ixazomib in combination
with lenalidomide–dexamethasone. Western patients received
ixazomib as a single agent or in combination with lenalidomide–
dexamethasone
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3 months.
A total of 24 patients (56 %) had TEAEs requiring dose
reduction of at least one of the study drugs. The most
common were thrombocytopenia (seven patients, 16 %),Table 3 Safety profile of ixazomib plus lenalidomide–dexamethason
AE, n (%) Chinese
(n = 20)
Any AE 20 (100
Any drug-related AE 19 (95)
Any grade ≥3 AE 12 (60)
Any drug-related grade ≥3 AE 7 (35)
Any SAEa 8 (40)
Any drug-related SAE 3 (15)
AE resulting in any study drug dose reduction, n (%) 12 (60)
AE leading to discontinuation, n (%) 4 (20)
On-study deaths, n (%) 0
AE adverse event, SAE serious adverse event
aDefined as any AE or adverse reaction that results in death, is life-threatening, requ
results in persistent or significant disability or incapacity, or is a congenital anomalyfatigue, neutropenia, increased blood creatinine (each
in three patients, 7 %), diarrhea, and PN (each in two
patients, 5 %). Seven patients had TEAEs leading to
discontinuation of at least one of the study drugs;
these included pneumonia (two patients), acute renal
impairment, plasmacytoma due to progressive disease,
drug hypersensitivity, thrombocytopenia, spinal cord
compression due to progressive disease, and worsen-
ing of PN (each in one patient). Ten (23 %) patients
had at least one drug-related serious AE (SAE); diar-
rhea (three patients, 7 %) and pneumonia (two pa-
tients, 5 %) were the only drug-related SAEs seen in
>1 patient. There were no on-study deaths.
Response
To date, 28 of 43 response-evaluable patients have
had a response (confirmed or unconfirmed), giving an
ORR (PR or better) of 65 %. Ten (23 %) patients
achieved ≥VGPR, including four (9 %) who attained a
complete response (CR). A further five (12 %) pa-
tients had stable disease. Thirty (83 %) of the 36
patients in the safety population with measureable
M-protein data had a >25 % decrease in the best
percent change in M-protein, and 28 (78 %) patients
had a >50 % decrease (Additional file 1: Figure S1).
To date, of the 23 responders with a confirmed
response, six have progressed, with a median duration
of response of 12.9 months.
Discussion
This is the first report of the all-oral combination of
weekly ixazomib plus lenalidomide–dexamethasone in
East Asian patients with RRMM. There were no DLTs in
the first six patients who received the starting ixazomib
dose of 4.0 mg, and the recommended weekly ixazomib
dose was thus determined as 4.0 mg per protocol, the
same as reported in Western patients [13, 14, 20]. Thee, overall and by East Asian ethnicity
Korean Other Overall
(n = 16) (n = 7) (N = 43)
) 16 (100) 7 (100) 43 (100)
11 (69) 7 (100) 37 (86)
12 (75) 7 (100) 31 (72)
8 (50) 6 (86) 21 (49)
5 (31) 5 (71) 18 (42)
4 (25) 3 (43) 10 (23)
7 (44) 5 (71) 24 (56)
2 (13) 1 (14) 7 (16)
0 0 0
ires hospitalization or prolongation of existing hospitalization,
or birth defect
Table 4 Most common any grade (>10 % of patients) and grade ≥3 (>1 patient) drug-related AEs
Chinese (n = 20) Korean (n = 16) Other (n = 7) Overall (N = 43)
Any grade AE, n (%)
Skin/subcutaneous tissue disordersa 10 (50) 4 (25) 7 (100) 21 (49)
Diarrhea 10 (50) 4 (25) 3 (43) 17 (40)
PN NECb 4 (20) 3 (19) 4 (57) 11 (26)
Vomiting 4 (20) 3 (19) 2 (29) 9 (21)
Neutropenia 3 (15) 4 (25) 1 (14) 8 (19)
Thrombocytopenia 2 (10) 4 (25) 2 (29) 8 (19)
Decreased appetite 5 (25) 0 3 (43) 8 (19)
Fatigue 2 (10) 1 (6) 4 (57) 7 (16)
Nausea 2 (10) 4 (25) 1 (14) 7 (16)
Decreased platelet count 3 (15) 2 (13) 0 5 (12)
Insomnia 3 (15) 0 2 (29) 5 (12)
Grade ≥3 AE, n (%)
Neutropenia 3 (15) 4 (25) 1 (14) 8 (19)
Thrombocytopenia 1 (10) 2 (25) 2 (29) 5 (12)
Diarrhea 0 4 (25) 2 (29) 6 (14)
Fatigue 1 (5) 1 (6) 2 (29) 4 (9)
Anemia 1 (5) 0 2 (29) 3 (7)
Hypokalemia 1 (5) 0 2 (29) 3 (7)
AE adverse event, PN NEC peripheral neuropathy not elsewhere classified
aSystem organ class, includes the preferred terms dry skin, macular rash, pruritus, skin hyperpigmentation (each n = 4), generalized pruritus, pruritic rash (each
n = 3), maculopapular rash, skin exfoliation (each n = 2), skin discoloration, dermatitis acneiform, night sweats, drug eruption, papular rash, pigmentation disorder,
and abnormal hair growth (each n = 1)
bHigher level term, includes the preferred terms peripheral neuropathy (n = 9) and peripheral sensory neuropathy (n = 2)
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parable to that reported in Western patients with
NDMM who received ixazomib (4.0 mg) in combination
with lenalidomide–dexamethasone [14]. Furthermore,
preliminary efficacy data indicate that the regimen could
be active in East Asian patients with RRMM. On the
basis of the PK, safety, and preliminary efficacy data re-
ported here, Asian patients are eligible for enrollment in
the ongoing ixazomib phase 3 studies and will receive
the same dose as administered in other regions.
When administered in combination with lenalido-
mide–dexamethasone in East Asian patients, ixazomib
was rapidly absorbed with a median time to maximum
plasma concentration of about 1.5–2 h. As seen in pre-
vious PK studies of ixazomib [13–15, 21], the long ter-
minal half-life of ixazomib in this study (geometric
mean of 6.1 days) supports weekly dosing. As reported
for other agents [22, 23], the PK profile of ixazomib ad-
ministered in combination with lenalidomide–dexa-
methasone was largely similar across the different East
Asian races (e.g., Chinese, Korean), indicating no re-
gional differences according to ethnicity and supporting
the use of the same dose across East/North Asia. The
PK profile reported here appears largely similar to
that reported in a phase 1 study of ixazomib pluslenalidomide–dexamethasone in Western NDMM pa-
tients (NCT01217957) [14]. When pooling data from
three studies in Western patients [13, 14, 24], ixazo-
mib geometric mean DN AUC0–168 was found to be
28 % higher than East Asian RRMM patients on day
1 of dosing (194 [78 % CV] vs 152 [95 % CV] ng*h/
mL/mg, respectively) and 49 % higher on day 15 (401
[48 % CV] vs 269 [44 % CV] ng*h/mL/mg, respect-
ively). However, these increases in geometric mean
exposure in East Asian patients are modest when
viewed in the context of associated PK variability. Im-
portantly, ixazomib exposures in Asian patients at the
global phase 3 dose of 4.0 mg are not expected to ex-
ceed the exposures at the MTD in Western patients
(2.97 mg/m2, which equates to 5.5 mg) [20], con-
sistent with the safety and tolerability findings re-
ported here with only 2 of 24 DLT-evaluable patients
experiencing DLTs in cycle 1. Future population PK
analyses will statistically evaluate the potential contri-
bution of race to overall PK variability.
Overall, the regimen appears well tolerated in East
Asian patients with RRMM. As seen in a phase 1 study
of ixazomib plus lenalidomide–dexamethasone in West-
ern patients [14], AEs were generally manageable with
clinical intervention or dose modification. Consistent
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the most common drug-related grade ≥3 AEs were
hematologic AEs, most commonly neutropenia and
thrombocytopenia (seen in 19 % and 12 % of East Asian
patients and 14 % and 8 % of Western patients, respect-
ively), in both patient populations. Overall, median
changes from baseline in neutrophil and platelet counts
were generally small and not clinically relevant; during
the first 3 cycles, a rapid decrease in platelets was ob-
served at the beginning of the cycle followed by recov-
ery before the next cycle. Also consistent with previous
reports on the safety profile of ixazomib in Western
patients [13–15, 21], but in contrast to data for the bor-
tezomib–lenalidomide–dexamethasone triplet regimen
(53 % sensory neuropathy, 17 % neuropathic pain, and
14 %, including 3 % grade 3, motor neuropathy) [9], the
incidence of PN was low (26 %), and there were no re-
ports of grade ≥3 PN. The tolerability of this regimen
also compares favorably to that reported for the carfil-
zomib–lenalidomide–dexamethasone triplet regimen in
patients with RRMM following 1–3 prior therapies [10],
with similar low rates of PN but no drug-related cardiac
toxicities.
The all-oral combination of ixazomib plus lenalido-
mide–dexamethasone has demonstrated encouraging
anti-tumor activity in a phase 1/2 study in Western
patients with NDMM. Following these early-phase
data, the regimen is being investigated in two phase 3
studies in patients with MM: TOURMALINE-MM1
(NCT01564537), investigating weekly oral ixazomib or
placebo plus lenalidomide–dexamethasone in patients
with RRMM, and TOURMALINE-MM2 (NCT01850524),
investigating weekly oral ixazomib or placebo plus lenali-
domide–dexamethasone in patients with NDMM who are
transplant-ineligible. This phase 1 study confirmed that
4.0 mg ixazomib, the phase 3 dose for Western patients,
combined with lenalidomide and dexamethasone, is effect-
ive and well tolerated in Asian patients with RRMM. The
RP2/3D for ixazomib combined with lenalidomide and
dexamethasone is 4.0 mg in Asian patients with RRMM.
Methods
Patients
East Asian patients aged ≥18 years with RRMM following
1–3 prior lines of therapy, measurable disease (serum M-
protein ≥1 g/dL, urine M-protein ≥200 mg/24 h, or in-
volved free light chain ≥10 mg/dL), Eastern Cooperative
Oncology Group performance status 0–2, and adequate
hepatic (bilirubin ≤1.5 × upper limit of normal [ULN], ala-
nine aminotransferase and aspartate aminotransferase ≤3
× ULN), renal (calculated creatinine clearance ≥30 mL/
min), and hematologic (absolute neutrophil count ≥1000/
mm3, platelet count ≥75,000/mm3) function were eligible.
Patients with grade ≥2 PN or grade 1 PN with pain, or anyco-morbid systemic illness or other severe concurrent dis-
ease that, in the judgment of the investigator, would make
the patient inappropriate for entry into the study or inter-
fere significantly with the proper assessment of safety and
toxicity of the prescribed regimens were not eligible. Pa-
tients who received systemic treatment, within 14 days be-
fore study enrollment, with strong inhibitors of CYP1A2,
strong inhibitors of CYP3A, or strong CYP3A inducers, or
used Ginkgo biloba or St. John’s wort were also not
eligible.
Study design
The primary objectives of this multicenter, phase 1 PK, tol-
erability, and dose-determination study were to characterize
the plasma PK parameters of ixazomib administered in
combination with lenalidomide and low-dose dexametha-
sone, determine the RP2/3D, and evaluate the safety and
tolerability in East Asian patients. Secondary objectives in-
cluded evaluation of the ORR, defined as partial response
or better.
The patients received oral ixazomib weekly on days 1,
8, and 15, lenalidomide (25 mg) on days 1–21, and dexa-
methasone (40 mg) on days 1, 8, 15, and 22, in 28-day
cycles until progressive disease or unacceptable toxicity.
Ixazomib was taken at least 1 h before or 2 h after a
meal; when applicable, ixazomib and lenalidomide were
taken at the same time. Dexamethasone was taken at
least 1 h after ixazomib and lenalidomide administration.
Lenalidomide starting dose was adjusted for patients with
renal impairment based on local prescribing information.
All patients received mandatory thromboprophylaxis with
aspirin, low-molecular-weight heparin, or an alternative
agent according to the American Society of Clinical On-
cology guidelines [25] or institutional standards of care,
and as required by the lenalidomide prescribing informa-
tion label. Dose modifications could be made based on
toxicities. Concomitant administration of strong inhibitors
of CYP1A2, strong inhibitors of CYP3A, or G. biloba or
St. John’s wort was not permitted; concomitant adminis-
tration of strong CYP3A inducers was to be avoided.
DLTs were defined as one or more of the following tox-
icities considered related to therapy: (1) grade 4 neutro-
penia lasting ≥7 days or grade 3 neutropenia with fever
(≥38.5 °C) and/or infection; (2) grade 4 thrombocytopenia
lasting ≥7 days, grade 3 thrombocytopenia with clinically
significant bleeding, or platelets <10 000/mm3 at any time;
(3) any grade ≥3 non-hematologic toxicity except grade 3
arthralgia/myalgia and brief (<1 week) grade 3 fatigue; (4)
grade 2 PN with pain; (5) a delay of ≥2 weeks in starting
cycle 2 due to lack of recovery from ixazomib-related tox-
icities in cycle 1; or (6) other study drug-related grade ≥2
non-hematologic toxicities requiring drug discontinuation.
DLTs were assessed in cycle 1, and DLTs observed dur-
ing cycle 1 in the first six patients were used to
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The starting dose of ixazomib was 4.0 mg (the RP2/3D
in Western patients with NDMM [14, 20]), with
planned dose de-escalation to 3.0 mg and then 2.3 mg,
following a standard 3 + 3 design, if the starting dose
was not acceptably tolerated in East Asian patients
(Additional file 1: Figure S2).
All patients provided written informed consent, and
review boards at all participating centers approved the
study protocol and protocol amendments, and the trial
was conducted according to the stipulations set out in
the Declaration of Helsinki and International Conference
on Harmonisation Guideline for Good Clinical Practice.
The study was registered at www.clinicaltrials.gov as
NCT01645930.
Assessments
Blood samples for PK analysis of ixazomib were col-
lected at prespecified time points during cycle 1 (within
1 h pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 8, 24, 48, 96, and
168 h post-dose on days 1 and 15) and within 1 h prior
to dosing on day 1 of cycle 2. Ixazomib plasma concen-
trations were measured using a validated liquid chroma-
tography/tandem mass spectrometry (LC/MS/MS) assay.
AEs were evaluated throughout and up to 30 days after
the last dose of study medication and were graded ac-
cording to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events (NCI-CTCAE)
v4.03. Response was assessed by investigators every
other cycle using the International Myeloma Working
Group uniform response criteria [26].
Statistical analyses
All patients who received at least one dose of study drug
were included in the safety population; those who also
had at least one post-treatment response evaluation were
included in the response-evaluable population. The
DLT-evaluable population included all patients who had
a DLT during cycle 1 or received all scheduled doses
and completed all study procedures in cycle 1 without
having a DLT.
Plasma PK parameters were calculated for patients in the
safety population following administration of ixazomib on
cycle 1 day 1 and/or cycle 1 day 15 provided sufficient con-
centration–time data were available, the patient had re-
ceived the protocol-specified ixazomib dosing regimen
during cycle 1, and no excluded concomitant medications
were received during the PK sampling period. PK parame-
ters were estimated using non-compartmental analysis
methods from the ixazomib concentration versus time data.
The analyses were performed using Phoenix WinNonlin
version 6.2 (Pharsight, Princeton, NJ). PK parameters were
summarized, as appropriate, using descriptive statistics. DN
AUC data in East Asian patients were compared with datafor Western patients, pooled from three phase 1/2 trials of
patients with RRMM (NCT00963820) [13], NDMM
(NCT01217957) [14], and relapsed/refractory AL amyloid-
osis (NCT01318902) [16].Additional file
Additional file 1: Figure S1. Waterfall plot of the best percent change
in M-protein from baseline. Figure S2. Flowchart for ixazomib dose
determination during cycle 1.Competing interests
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